摘要
Results of the ELDERCARE-AF trial have been presented at the ESC Congress 2020 and simultaneously published in the New England Journal of Medicine (https://doi.org/10.1056/NEJMoa2012883). Key Points • ELDERCARE-AF is a company-sponsored, multicentre, double-blind trial that randomly assigned 984 very elderly Japanese patients (mean age 87 ± 4 years) with non-valvular atrial fibrillation (NVAF) and a CHADS2 score ≥2 (mean 3.1) to receive a once-daily 15-mg dose of the factor-Xa inhibitor edoxaban or placebo. Participants had poor renal function (mean creatinine clearance, 36 ± 14 mL/min), low body weight (51 ± 11.0 kg), a history of serious bleeding, continuous use of non-steroidal anti-inflammatory drugs (NSAIDs), or current use of an antiplatelet drug, all conditions that made them inappropriate candidates for direct oral anticoagulant (DOAC) therapy at doses approved for stroke prevention. • Low-dose edoxaban significantly reduced the primary efficacy endpoint, stroke, or systemic embolism, by 66% (15 vs. 44 events; 2.3% vs. 6.7% per year; P < 0.001; number needed to treat = 23). The benefit of edoxaban was largely explained by a large reduction in ischaemic stroke. There was an increase in the primary safety endpoint of major bleeding (International Society on Thrombosis and Haemostasis criteria) in the edoxaban group versus placebo (20 vs. 11 events; 3.3% vs. 1.8% per year; hazard ratio = 1.87; 95% confidence interval 0.90–3.89; P = 0.09). A non-significant P-value for such a difference reflects the inadequate statistical power of the study. The 1.5% absolute excess in major bleeding was explained by a three-fold higher number of gastrointestinal bleeding events (14 vs. 5 events; 2.3% vs. 0.8% per year). • There was no between-group difference in death from any cause (9.9% and 10.2% in the edoxaban and placebo groups, respectively). Results of the ELDERCARE-AF trial have been presented at the ESC Congress 2020 and simultaneously published in the New England Journal of Medicine (https://doi.org/10.1056/NEJMoa2012883). Direct oral anticoagulants are first-line treatment for NVAF patients to reduce the risk of stroke. However, DOACs are underused or prescribed at inappropriate doses for stroke prevention in elderly NVAF patients who face a higher risk of both ischaemic and haemorrhagic complications, because of a history of bleeding, prior falls, polypharmacy, cognitive impairment, or frailty. In the ENGAGE AF-TIMI 48 trial, only 17% of patients were ≥80 years of age and 4% were aged ≥85; the study was not specifically designed to assess the efficacy and safety of edoxaban in frail elderly patients, not eligible for standard DOAC. The 15 mg dose of edoxaban was selected based on data from the ENGAGE AF-TIMI 48 trial and a previous pharmacokinetic study in elderly Japanese patients with AF. The annualized rate of stroke or systemic embolism with the 15 mg dose of edoxaban in ELDERCARE-AF (2.3%) was similar to that of the 60 mg and 30 mg dose regimens of edoxaban (2.5% and 2.8%, respectively) in the ENGAGE AF-TIMI 48 trial among patients aged ≥80, although that study included lower-risk patients. These findings may be partly explained by the higher plasma concentration of edoxaban with severe renal insufficiency and low body weight. Can we prevent stroke in elderly NVAF patients without increasing the risk of bleeding? Not surprisingly, major bleeding was more common with edoxaban, though with a favourable balance between benefit and harm. Low-dose edoxaban did not increase the risk of intracranial haemorrhage, while it tripled the rate of gastrointestinal bleeding in a population at very high risk of these complications because of advanced age, continuous use of NSAIDs (in about one-third of patients), and antiplatelet agents (in >50%). Moreover, edoxaban caused substantially more events of bleeding defined as secondary safety endpoints. Can we generalize the ELDERCARE-AF results and translate them into daily practice? This study has important limitations: (i) the trial discontinuation rates were quite high (nearly one-third), although similar in both groups and unrelated to bleeding; (ii) median body weight was approximately 50 kg, although body mass index was 22; and (iii) the trial only involved Japanese NVAF patients and the results may not be applicable to other populations. On the other hand, ELDERCARE-AF had the merit of selecting the edoxaban dose based on previous clinical experience and a pharmacokinetic study in the target patient group. This approach should be used to define the optimal dose of other DOACs in very elderly populations. In conclusion, for very elderly patients who would not otherwise receive a DOAC, edoxaban 15 mg (when and where available) may represent an acceptable treatment option to reduce the risk of stroke, although care should be taken to avoid gastrointestinal bleeding by appropriate management of other risk factors and use of proton pump inhibitors (their use in ELDERCARE-AF was not reported). Conflict of interest: Prof. Liuzzo received grant support (to the Institution) for investigator-initiated research from American Heart Association, Italian National Health Service and Italian Minister of Education University and Research. Prof. Patrono received consultant and speaker fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, Tremeau, Zambon, and grant support (to the Institution) for investigator-initiated research from AIFA (Italian Drug Agency), Bayer, Cancer Research UK and European Commission; he chairs the Scientific Advisory Board of the International Aspirin Foundation.